Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Comorbidities: Linked by Vascular Pathomechanisms and Vasoactive Mediators?
Wirth, Klaus J, Löhn, Matthias · Medicina (Kaunas, Lithuania) · 2023 · DOI
Quick Summary
This study examines why ME/CFS patients often experience other conditions like POTS, mast cell activation, endometriosis, and small fiber neuropathy at the same time. The researchers analyzed how these conditions might share common problems with blood vessel function and chemical messengers in the body. They found strong evidence that excessive inflammatory chemicals and problems with a specific receptor in the body (β2AdR) may be the connecting link between all these conditions.
Why It Matters
Understanding that ME/CFS shares common vascular and inflammatory mechanisms with its associated conditions could lead to more unified treatment approaches and better clinical management of patients who have multiple comorbidities. This framework may help explain why patients experience such a constellation of symptoms and could guide development of therapies targeting the root causes rather than individual conditions separately.
Observed Findings
ME/CFS, mast cell activation, endometriosis, dysmenorrhea, POTS, decreased cerebral blood flow, and small fiber neuropathy share evidence of excessive inflammatory and vasoactive mediator generation and spillover.
All reviewed conditions show evidence of β2-adrenergic receptor dysfunction.
Vascular dysfunction appears as a common feature across all examined comorbidities.
These conditions frequently co-occur in the same patients, suggesting shared pathophysiological mechanisms.
Inferred Conclusions
Vascular dysfunction and excessive vasoactive mediator spillover are the primary pathomechanisms linking ME/CFS with its common comorbidities.
Dysfunctional β2-adrenergic receptor signaling is a key shared mechanism across these conditions.
The mutual triggering of symptoms among these conditions suggests they may share root causes rather than existing as independent disorders.
Targeting these common vascular and inflammatory mechanisms could offer a unified therapeutic approach for patients with multiple comorbidities.
Remaining Questions
Which condition initiates the cascade of pathology, and what is the primary trigger (environmental, genetic, infection-related, or other)?
How do these proposed mechanisms differ across individual patients, and are there patient subgroups with distinct pathophysiological profiles?
What This Study Does Not Prove
This analysis does not provide experimental proof of causation—it is a theoretical synthesis of existing research. It does not prove that all ME/CFS patients with comorbidities share identical mechanisms, nor does it establish which condition triggers the others or whether they share a single common cause versus having overlapping independent pathways.
Tags
Method Flag:EXPLORATORYPEM_UNCLEARExploratory Only
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.